Docetaxel

Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.

Hossein Borghaei, DO, MS, spoke with Healio about findings from the S1800A Lung-MAP substudy and CheckMate 816.

In this video, Ravi Salgia, MD, PhD, discussed findings from two studies presented at ASCO Annual Meeting — one investigating immunotherapy and the other targeted therapy — for the treatment of lung cancer.

In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.

CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results presented at ASCO Annual Meeting.

Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, spoke with Healio about results from the ARASENS trial presented at the 2022 ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.

The addition of docetaxel to cisplatin and 5-FU chemotherapy significantly extended OS as neoadjuvant therapy for local advanced esophageal squamous cell cancer, according to results of a randomized phase 3 trial.

In this video, Ben Tran, MD, discusses the PEACE-1 and STAMPEDE studies that looked at the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy, which was found to improve survival vs. standard therapy.

Women with breast cancer and overweight or obesity had shorter DFS and OS than their lean counterparts after treatment with a docetaxel-based chemotherapy regimen, according to study results published in Journal of Clinical Oncology.